Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 2020

View Archived Issues

A Tau-sand forms of tau?

FDA approves IND for SFA-002 study in psoriasis

GDF-15 proposed as a biomarker for coronary artery lesions in Kawasaki disease

miR-375 and miR-3687 are potential prognostic markers in enzalutamide-treated patients with mCRPC

SARS-CoV-2 Ab cocktails binding to distinct nonoverlapping regions of S protein prevent viral escape

Zanubrutinib demonstrates durable responses in patients with marginal zone lymphoma

RevImmune launches phase II U.K. study of CYT-107 for COVID-19

Preclinical studies show promise of GLP-1R agonist GL-0034 for treating diabetes

Japanese approval for Samsca for hyponatremia secondary to SIADH in adults

Shape-shifting DENV3 evades vaccines, therapeutics

Interim data reported from phase I study of INO-4800 vaccine for COVID-19

Antag Therapeutics describes new gastric inhibitory polypeptide receptor antagonists

Topline data from pivotal CONNECT-FX study of Zygel in fragile X syndrome

Dosing completed in first dose-escalation cohorts of phase I/II study of RTX-240

New galectin-3 inhibitors discovered at Bristol-Myers Squibb

Novartis patents chondrogenesis inducers

Shanghai Jemincare Pharmaceuticals, Jiangxi Jemincare Group disclose S1P1 agonists

New PI3K inhibitors identified at Innovent Biologics

Researchers present preclinical data on EDIT-301 for sickle cell disease

Exelixis initiates phase III CONTACT-02 study of cabozantinib plus atezolizumab in CRPC

Ilumya approved in Japan for plaque psoriasis

Hoth enters sponsored research agreement with VCU for potential peptide COVID-19 therapeutic

Bavencio approved in U.S. as first-line maintenance in urothelial carcinoma

Innovent Biologics' bispecific antibody IBI-323 blocks PD-L1 and LAG-3

Amniox begins first phase III trial of TTAX-01 in diabetic foot ulcers

Lysogene collaborates with Weizmann Institute of Science on gene therapy for Gaucher and Parkinson's

FDA approves Dojolvi for long-chain fatty acid oxidation disorders

Corcept opens phase III study of relacorilant with nab-paclitaxel for metastatic pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...